Heparin-induced thrombocytopenia type II in an infant with a congenital heart defect--anticoagulation during cardiopulmonary bypass with epoprostenol sodium and heparin.

Abstract

BACKGROUND:

Heparin-induced thrombocytopenia type II (HIT II) is a rare but potentially life-threatening complication of heparin therapy. Hitherto, only few reports on HIT II in infants and children have been published. In particular, infants and children who have to be operated under cardiopulmonary bypass are at risk as an alternative anticoagulation is required.

CASE PRESENTATION:

We report on an infant with a congenital heart defect who was scheduled for cardiac surgery (Damus Kaye-Stansel procedure) with cardiopulmonary bypass. In the intensive care unit, an HIT II was diagnosed. Before surgery, the infant was pretreated with epoprostenol sodium (incrementally increasing up to a maximum dose of 30 ng/kg/min) before heparin was administered shortly after sternotomy. Mean arterial pressure was kept stable with an infusion of norepinephrine and the course of the cardiopulmonary bypass showed no signs of thrombosis. Drainage loss in the postoperative period was moderate.

CONCLUSION:

In HIT II infants, pretreatment with epoprostenol sodium before reexposure to heparin may offer a safe and effective anticoagulation for cardiopulmonary bypass.

• Authors: Christian von Heymann, Elmar Hagemeyer, Marc Kastrup, Sabine Ziemer, Hans Proquitté, Wolfgang F Konertz, Claudia Spies
• Journal: Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (Pediatr Crit Care Med) Vol. 7 Issue 4 Pg. 383-5 (Jul 2006) ISSN: 1529-7535 [Print] United States
• PMID: 16738494 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anticoagulants
• Platelet Aggregation Inhibitors
• Heparin
• Epoprostenol

Topics

• Anticoagulants (administration & dosage, adverse effects)
• Cardiopulmonary Bypass
• Drug Therapy, Combination
• Epoprostenol (administration & dosage)
• Female
• Heart Defects, Congenital (surgery)
• Heparin (administration & dosage, adverse effects)
• Humans
• Infant
• Platelet Aggregation Inhibitors (administration & dosage)
• Premedication
• Thrombocytopenia (chemically induced, prevention & control)